Nanjing Leads Biolabs Co Ltd
Company Profile
Business description
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. It has one Core Product, LBL-024 (registrational-stage PD-L1 and 4-1BB dual-targeting bispecific antibody), which it is evaluating for its therapeutic potential in extra-pulmonary neuroendocrine carcinoma both as monotherapy for patients who have received at least three prior lines of therapy and part of combination therapy as first-line treatment (1L), as well as in small cell lung cancer as 1L treatment, biliary tract cancer as 1L/1L+ treatment, non-small cell lung cancer as 1L/1L+ treatment, and other solid tumors in patients who have received at least two prior lines of therapy.
Contact
18E, Jialingjiang Street
Floor 8, Building 03
Jiangsu
Nanjing210019
CHNT: +86 2558862889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
192
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
stocks
Is the market still overlooking Alibaba’s AI potential?
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,923.45 | 53.11 | 0.67% |
| DAX 40 | 24,359.30 | 18.20 | -0.07% |
| Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
| FTSE 100 | 9,138.90 | 38.34 | -0.42% |
| HKSE | 25,270.07 | 249.25 | -0.98% |
| NASDAQ | 21,622.98 | 87.69 | -0.40% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,449.80 | 18.74 | -0.29% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,696.77 | 30.33 | 0.83% |